An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms

NCT ID: NCT07078682

Last Updated: 2025-09-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-01

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a 24-week, single-arm, open-label, virtual study evaluating the effects of Elix Cycle Balance and Elix Daily Harmony on uterine fibroid-related symptoms and quality of life in 42 participants. Participants will self-administer the investigational herbal supplements daily and complete validated questionnaires at scheduled timepoints to assess symptom severity and quality of life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uterine Fibroids Leiomyoma Menstrual Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Elix Cycle Balance & Elix Daily Harmony

Participants will receive two investigational herbal supplements daily for 24 weeks.

Group Type EXPERIMENTAL

Elix Daily Harmony

Intervention Type DIETARY_SUPPLEMENT

Each morning, 1-2 hours after their first meal, they will mix the following into room-temperature or warm water and consume:

Elix Daily Harmony: 3 droppers full (approximately 2.5 mL) Elix Cycle Balance: 6 droppers full (approximately 5.0 mL)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Elix Daily Harmony

Each morning, 1-2 hours after their first meal, they will mix the following into room-temperature or warm water and consume:

Elix Daily Harmony: 3 droppers full (approximately 2.5 mL) Elix Cycle Balance: 6 droppers full (approximately 5.0 mL)

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be female.
* Be aged 20-45.
* BMI 18.5 - 24.9 kg/m2
* Self-reported prior diagnosis of uterine fibroids.
* Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
* Self-reported moderate to severe discomfort during menstruation, related to pelvic cramps, bloating, mood swings, or fatigue.
* Self-reported menstrual cramps during their cycle, for the past six months minimum.
* If taking hormonal birth control, has been doing so consistently for at least three months, and experiences a menstrual cycle with a period.
* If taking other oral over-the-counter supplements or herbal remedies, has been consistently taking these for at least three months prior to starting the study, and is willing to maintain this routine for the study duration.
* Willing to refrain from introducing any products or any new forms of medication or supplements for the study duration.
* Willing to refrain from any other dietary supplements or herbal remedies targeting the menstrual cycle during the study period.
* Willing to refrain from any new vaccines during the 6 month period.
* Follows a stable, consistent exercise regimen and are willing, for the duration of the study, to not decrease or increase the amount of exercise in their regimen.
* Agrees to refrain from any lifestyle changes that may affect their menstrual cycle for the duration of the study (for example, getting on or off hormonal birth control, reducing the amount of exercise).
* If using any other interventions, such as massage, chiropractic medicine, or acupuncture, agrees not to increase or decrease the number of these other interventions during the study period.
* Resides in the United States.

Exclusion Criteria

* Does not experience a regular menstrual cycle (21-35 days).
* Does not experience menstrual cramping.
* Follows an extreme diet intervention such as dry fasts, water fasts, or ketogenic diets.
* Anyone who has experienced significant weight loss in the past three months prior to study participation.
* Unwilling to stop the use of any medication or herbal remedies/supplements that can affect the menstrual cycle.
* Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
* Anyone with known severe allergic reactions.
* Anyone with any allergies or sensitivities to any of the study product ingredients.
* Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
* Anyone unwilling to follow the study protocol.
* Has stopped, started, or changed hormonal birth control in the past three months.
* Previous users of Elix Cycle Balance.
* Anyone who is currently a smoker or has been a smoker in the past 3 months.
* Anyone who has been diagnosed with the following conditions: PCOS, Endometriosis, PMDD, Adenomyosis, Hashimoto's thyroiditis, Grave's disease (and any other thyroid disorders), hyperprolactinemia, Cushing's disease, congenital adrenal hyperplasia, anorexia, bulimia, orthorexia, binge eating, any other eating disorder.
* History of endocrine disorders such as thyroid disorder, Type 1 or 2 diabetes, or other.
* History of hypertension, hyperlipidemia, or previous venous embolism.
* Overweight/obesity (BMI \> 25 kg/m2).
* Women with other causes of chronic pelvic pain, including infectious disease, gastrointestinal, psychological disorders, fibromyalgia, and chronic fatigue syndrome.
* Hysterectomy, myomectomy, or bilateral salpingo-oophorectomy or other gynecological medical or surgical treatment in the last 6 months.
* History of an abnormal pap smear.
* History of neoplasia of gynecological origin and/or existence of uterine malformations.
* Chronic urinary tract infections or diagnosed functional gastrointestinal conditions like IBS, IBD, Crohn's disease, or ulcerative colitis.
* Currently partaking in another research study or will be partaking in any other research study for the next 24 weeks, or at any point during this study's duration.
* Consume more than 5 alcoholic drinks per week
* Had a vaccine in the last 3 months
Minimum Eligible Age

20 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Citruslabs

INDUSTRY

Sponsor Role collaborator

Zenchi, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Citruslabs

Las Vegas, Nevada, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Patrick Renner, MSc

Role: CONTACT

4242450284

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Patrick Renner, MSc

Role: primary

424-245-0284

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20790

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.